All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches

Faculty

Aaron T. Gerds, MD, MS
Associate Professor of Medicine, Hematology & Medical Oncology
Deputy Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute
Medical Director, Case Comprehensive Cancer Center Clinical Research Office
Cleveland, OH

Statement of Need

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis) in MF. These clinicians and their interdisciplinary collaborative care team need a deeper understanding of JAKis in MF, guideline-recommended risk-stratification algorithms, molecular indicators of disease prognosis, clinical features of MF, symptom burden, the impact of adverse events on treatment adherence, and health disparities in MF.  


In this CE Concepts Grand Rounds series, expert faculty will discuss assessing patients for MF therapy, integrating current and emerging data on JAKis in MF, developing individualized strategies to reduce treatment toxicity and enhance treatment adherence, and evaluating health disparities in MF.
The faculty will also provide insight through case examples. 

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Assess patients for MF therapy utilizing guideline-recommended risk-stratification algorithms as well as molecular indicators of disease prognosis, clinical features, and symptom burden
  • Integrate current and emerging data on JAKis when choosing the most suitable MF treatment for each individual patient
  • Develop individualized strategies to reduce treatment toxicity and enhance treatment adherence for patients with MF
  • Evaluate current health disparities impacting treatment outcomes in MF, including consideration of clinical trial participation opportunities for patients in underserved populations

Financial Support

Supported by an independent medical educational grant from CTI Biopharma Corp., a Sobi company, and GSK.

Target Audience

Community and academic hematologists, hematologists/oncologists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists who care for patients with MF

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Council for Pharmacy Education

This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-24-016-L01-P).

American Nurses Credentialing Center

This activity is designated for 1.00 contact hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

American Nurses Credentialing Center with ILNA

This activity is designated for 1.00 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

OCN®
​​Care Continuum
​​Oncology Nursing Practice
​​Psychosocial Dimensions of Care
​​Treatment

CBCN®
​​Care Continuum
​​Psychosocial Dimensions of Care
​​Treatment

CPHON®
​​Care Continuum
​​Psychosocial Dimensions of Care
​Treatment

AOCNP®
​​Care Continuum
​Professional Practice/Performance
​​Psychosocial Dimensions of Care
​​Roles of the APRN
​​Treatment

BMTCN®
​​Professional Practice/Performance

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CE Concepts, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Gerds reports the following financial relationships:

Advisory Board: AbbVie Inc.; Agios Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Disc Medicine; and GSK

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
Susan Perry (Planning Committee)
Katherine Lee, PharmD, MPH (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

GR-060

Call us at 859-260-1717  •  info@ceconcepts.com

All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches
Activity Date: 12/16/2024 at 12:00 PM EST